Business Context and Reporting Period
This Form 8-K was filed by Atyr Pharma, Inc. on April 3, 2017. The report discloses a corporate governance event: the appointment of a new member to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The material change reported is the appointment of Jeffrey S. Hatfield to the Board of Directors, effective April 3, 2017. Key details include:
- Role: Class III Director, serving until the 2018 annual meeting or until a successor is elected.
- Compensation: Cash and equity compensation per the non-employee director policy.
- Equity Grant: An option to purchase 32,000 shares of Common Stock.
- Exercise Price: Set at the closing price on April 3, 2017.
- Vesting: Equal monthly installments over three years, contingent on continued service.
Management Commentary and Background
Mr. Hatfield brings significant biopharmaceutical experience, having previously served as President and CEO of Vitae Pharmaceuticals (2004–2016) and held executive roles at Bristol-Myers Squibb. He currently serves on the board of InVivo Therapeutics and holds advisory roles at Purdue University, Drexel University, and Chapman-KGI School of BioPharmacy. The filing confirms no undisclosed transactions or arrangements influenced his selection.
Investor Verification Checklist
- Verify the closing stock price on April 3, 2017, to determine the exercise price of the 32,000 share option.
- Review the Company's non-employee director compensation policy for details on cash compensation.
- Confirm the vesting schedule and any acceleration clauses in the standard indemnification agreement.
- Check for any subsequent filings regarding Mr. Hatfield's committee assignments or potential conflicts of interest.